"The American Heart Association/American Stroke Association has issued a new scientific statement on the rationale for the inclusion and exclusion criteria for intravenous alteplase (tissue plasminogen activator [tPA]) in acute ischemic stroke."...
(ranolazine) Extended-release Tablets
RANEXA (ranolazine) Extended-release Tablets
Ranolazine is a racemic mixture, chemically described as
(±)-. It has an empirical formula of C24H33N3O4,
a molecular weight of 427.54 g/mole, and the following structural formula:
Ranolazine is a white to off-white solid. Ranolazine is soluble in dichloromethane and methanol; sparingly soluble in tetrahydrofuran, ethanol, acetonitrile, and acetone; slightly soluble in ethyl acetate, isopropanol, toluene, and ethyl ether; and very slightly soluble in water.
RANEXA tablets contain 500 mg or 1000 mg of ranolazine and the following inactive ingredients: carnauba wax, hypromellose, magnesium stearate, methacrylic acid copolymer (Type C), microcrystalline cellulose, polyethylene glycol, sodium hydroxide, and titanium dioxide. Additional inactive ingredients for the 500 mg tablet include polyvinyl alcohol, talc, Iron Oxide Yellow, and Iron Oxide Red; additional inactive ingredients for the 1000 mg tablet include lactose monohydrate, triacetin, and Iron Oxide Yellow.
What are the possible side effects of ranolazine (Ranexa)?
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:
- feeling like you might pass out;
- swelling in your hands, ankles, or feet;
- slow, fast, or pounding heartbeats;
- tremors or shaking;
- blood in your urine;
- urinating less than usual or not at all;
- shortness of breath; or
- skin rash, bruising, severe tingling, numbness, pain, and muscle...
Last reviewed on RxList: 1/9/2016
This monograph has been modified to include the generic and brand name in many instances.
Additional Ranexa Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.